PeptideJournal
Reference16 min read

Routes of Peptide Administration: Complete Guide

How a peptide enters the body determines how much of it actually reaches its target. A peptide injected subcutaneously might deliver 60-90% of the dose into the bloodstream. The same peptide swallowed as a pill might deliver less than 1%.

How a peptide enters the body determines how much of it actually reaches its target. A peptide injected subcutaneously might deliver 60-90% of the dose into the bloodstream. The same peptide swallowed as a pill might deliver less than 1%. These are not small differences --- they dictate dosing, cost, side effects, patient compliance, and ultimately whether a peptide can function as a practical drug.

Most approved peptide therapeutics are injectable. There is a reason for that: the human body is extremely good at destroying foreign peptides before they reach the circulation. But the field is changing. Oral semaglutide proved that oral peptide drugs can work. Nasal, transdermal, and pulmonary delivery systems are advancing. Understanding the strengths and limitations of each route is necessary for anyone studying peptide therapeutics or considering their clinical use.

Table of Contents

Why Administration Route Matters

Every route of administration imposes barriers between the drug and the bloodstream. These barriers determine bioavailability --- the fraction of the administered dose that reaches systemic circulation in active form.

For peptides, three barriers dominate:

Enzymatic degradation. Proteases in the GI tract, nasal mucosa, skin, and injection sites cleave peptide bonds. The gut is the harshest environment, with stomach acid (pH 1-3), pepsin, trypsin, chymotrypsin, and brush border peptidases working in sequence. But even subcutaneous tissue contains proteases that degrade a fraction of injected peptide before it reaches the blood.

Epithelial barriers. To reach the bloodstream, a peptide must cross an epithelial cell layer. Peptides are generally too large (molecular weight >500 Da), too hydrophilic, and too charged to passively diffuse through cell membranes. The intestinal epithelium, nasal mucosa, and skin stratum corneum each present distinct physical barriers.

First-pass metabolism. Peptides absorbed from the GI tract travel first to the liver via the portal vein. Hepatic enzymes can metabolize the peptide before it reaches systemic circulation. Routes that bypass the liver --- subcutaneous, nasal, transdermal, sublingual --- avoid this first-pass effect.

The choice of route for any given peptide balances bioavailability, onset speed, duration of action, patient convenience, and the peptide's specific physicochemical properties.

Subcutaneous Injection

Subcutaneous (SC) injection delivers the peptide into the fatty tissue layer beneath the skin, typically in the abdomen, thigh, or upper arm. It is the most common route for peptide therapeutics.

How It Works

The peptide is injected into the subcutaneous fat layer, where it forms a local depot. Absorption into the bloodstream occurs primarily through diffusion into surrounding capillaries and lymphatic vessels. The rate of absorption depends on blood flow at the injection site, the peptide's molecular weight, and any formulation factors (depot-forming excipients, viscosity).

Bioavailability

SC bioavailability for peptides typically ranges from 50% to 100%, depending on local enzymatic degradation and the peptide's properties. Small, stable peptides like insulin analogs achieve near-complete absorption. Larger or more protease-sensitive peptides may lose 20-40% to local degradation.

Advantages

  • Self-administration. Patients can inject at home with minimal training, using pens, auto-injectors, or standard syringes. For practical guidance, see our subcutaneous injection technique guide.
  • Sustained absorption. The subcutaneous depot provides slower, more sustained absorption compared to IV or IM injection, smoothing out peak-trough fluctuations.
  • Compatibility with long-acting formulations. Lipidated peptides like semaglutide, liraglutide, and tirzepatide are designed for SC administration, where slow absorption from the subcutaneous depot complements albumin binding to achieve extended durations.
  • Avoids first-pass metabolism. Peptide absorbed subcutaneously enters the systemic circulation directly.

Disadvantages

  • Injection site reactions. Redness, swelling, itching, or nodules at the injection site occur in a minority of patients, particularly with repeated dosing at the same location.
  • Injection burden. Even with modern pen devices, some patients are needle-averse. This is a significant barrier to adherence --- subcutaneously administered semaglutide showed the highest 1-year persistence among GLP-1 RAs, yet only 40% of patients were still on the medication at 12 months.
  • Variable absorption. Blood flow, fat layer thickness, injection depth, and site rotation all introduce variability in absorption kinetics.

Key Peptides Using SC Route

Most therapeutic peptides: insulin analogs, semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), liraglutide (Victoza/Saxenda), exenatide (Byetta/Bydureon), tesamorelin (Egrifta), octreotide (Sandostatin), and research peptides like BPC-157, CJC-1295, and ipamorelin.

Intramuscular Injection

Intramuscular (IM) injection delivers the peptide directly into skeletal muscle tissue, typically the deltoid, vastus lateralis (thigh), or gluteus.

How It Works

Muscle tissue has higher blood flow than subcutaneous fat, leading to faster absorption. The peptide diffuses from the injection site into the rich capillary network within muscle fibers, reaching the systemic circulation more rapidly than SC injection.

Bioavailability

Generally similar to SC injection (50-100%), though absorption kinetics differ. IM injection typically produces higher peak concentrations faster, while SC injection produces lower peaks over a longer period.

Advantages

  • Faster absorption. Higher muscle blood flow means faster onset of action compared to SC.
  • Larger volume capacity. IM sites can accommodate larger injection volumes (up to 5 mL in the gluteus) compared to SC (typically 1-2 mL).
  • Depot formulations. Long-acting depot formulations (microspheres, oil-based suspensions) injected IM can provide sustained release over weeks to months. Exenatide extended-release (Bydureon) is an IM depot that releases active peptide over one week.

Disadvantages

  • Pain. IM injections are more painful than SC, particularly for viscous formulations.
  • Requires proper technique. Incorrect needle length or angle can result in subcutaneous deposition instead of intramuscular, altering absorption kinetics.
  • Not ideal for self-administration. While possible (thigh injection), IM injection is more commonly performed by healthcare providers, particularly for gluteal or deltoid sites.

Key Peptides Using IM Route

Glucagon (emergency hypoglycemia), some vaccine adjuvant peptides, and certain depot formulations of GnRH analogs (leuprolide depot).

Intravenous Injection

Intravenous (IV) administration delivers the peptide directly into the bloodstream.

Bioavailability

By definition, IV administration provides 100% bioavailability. The entire dose reaches systemic circulation immediately. This is the reference standard against which all other routes are compared.

Advantages

  • Immediate onset. The peptide is in the blood within seconds. For emergency situations (e.g., vasopressin in cardiac arrest, octreotide for variceal bleeding), this speed is necessary.
  • Precise dosing. IV infusion allows exact control of plasma concentrations, including continuous infusions that maintain steady-state levels.
  • No absorption variability. No depot effects, no local degradation, no inter-patient variability in absorption.

Disadvantages

  • Requires clinical setting. IV administration needs venous access, typically placed by a healthcare professional. This limits use to hospitals, infusion centers, or home infusion setups.
  • Infection risk. Indwelling IV catheters carry risks of phlebitis, thrombosis, and bloodstream infection.
  • Rapid clearance of unmodified peptides. Without the depot effect of SC injection, unmodified peptides may be cleared very quickly, requiring continuous infusion rather than bolus dosing.
  • Cost and inconvenience. IV administration is the most expensive and least convenient route for chronic therapy.

Key Peptides Using IV Route

Oxytocin (labor induction), vasopressin (cardiac arrest, diabetes insipidus), octreotide (acute variceal bleeding), bivalirudin (anticoagulation during angioplasty), ziconotide (intrathecal, related to IV technique), and various peptide-drug conjugates in oncology.

Oral Administration

Oral delivery is the holy grail of peptide therapeutics. Patients overwhelmingly prefer pills over injections, and oral drugs dominate pharmaceutical sales for good reason: convenience, adherence, and non-invasiveness.

The Challenge

The GI tract is designed to dismantle proteins into amino acids. Oral peptides face a gauntlet:

  1. Stomach acid. pH 1-3 denatures tertiary structure and activates pepsin.
  2. Pepsin. Cleaves peptides at hydrophobic residues.
  3. Pancreatic proteases. Trypsin (cleaves at Arg/Lys), chymotrypsin (cleaves at aromatic/hydrophobic residues), and elastase (cleaves at small amino acids) attack in the duodenum.
  4. Brush border peptidases. Aminopeptidases and carboxypeptidases at the intestinal surface degrade small peptides.
  5. Epithelial barrier. The intestinal epithelium, connected by tight junctions, blocks paracellular transport of molecules larger than ~600 Da.
  6. Hepatic first-pass. Any peptide that survives the gut and crosses the epithelium enters the portal vein and may be metabolized by the liver before reaching systemic circulation.

The result: oral bioavailability for unformulated peptides is typically below 1-2%.

How Oral Peptide Drugs Work Anyway

Despite these barriers, several oral peptide drugs are approved or in development:

Oral semaglutide (Rybelsus). Co-formulated with the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate). SNAC raises local gastric pH, protects semaglutide from pepsin, and promotes transcellular absorption through the gastric epithelium. Bioavailability is approximately 1% --- but semaglutide is so potent that even 1% absorption at a 14 mg oral dose produces therapeutically effective plasma levels. Patients must take the tablet on an empty stomach with no more than 4 oz of water, then wait 30 minutes before eating or drinking --- constraints that directly reflect the fragile absorption window.

Desmopressin (DDAVP). A cyclic peptide analog of vasopressin, available as both an oral tablet and nasal spray. Oral bioavailability is approximately 0.1%, but the drug is potent enough at the low absorbed doses to treat diabetes insipidus and nocturnal enuresis.

Cyclosporine A (Neoral). A cyclic peptide immunosuppressant with 30% oral bioavailability --- exceptionally high for a peptide. Cyclosporine achieves this through extensive N-methylation (reducing protease susceptibility), a cyclic structure (increasing membrane permeability), and lipophilic character (facilitating absorption via the lymphatic system).

Orforglipron (Eli Lilly). A non-peptide, small-molecule GLP-1 receptor agonist that achieves oral bioavailability by being a small molecule rather than a peptide. While not technically a peptide, it targets the same receptor and represents the direction the field is moving: designing orally bioavailable molecules that mimic peptide actions.

Emerging Oral Delivery Technologies

Research is advancing on several fronts to improve oral peptide delivery:

  • Permeation enhancers beyond SNAC, including medium-chain fatty acids (C8-C12) and bile salt derivatives.
  • Mucoadhesive nanoparticles that attach to the intestinal wall and release peptide cargo over hours.
  • Enteric coatings that protect the peptide through the stomach and release it in the more neutral pH of the small intestine.
  • Ingestible injection devices (like Novo Nordisk's SOMA --- Self-Orienting Millimeter-scale Applicator) that orient in the stomach and inject the peptide directly through the gastric mucosa, bypassing the luminal degradation barrier entirely.

Nasal Administration

Nasal delivery offers a non-invasive alternative that bypasses GI degradation and hepatic first-pass metabolism. The nasal mucosa is thin, highly vascularized, and provides a large surface area (~150 cm2) for absorption.

How It Works

The peptide, formulated as a nasal spray or powder, is deposited on the nasal mucosa. Absorption occurs primarily through the respiratory epithelium via paracellular (between cells) and transcellular (through cells) pathways. The absorbed peptide enters the systemic circulation directly, avoiding first-pass hepatic metabolism.

Bioavailability

Nasal bioavailability for peptides is typically 1-10%, though this can be improved with absorption enhancers and mucoadhesive formulations. The limiting factor is rapid mucociliary clearance: the nasal mucosa regenerates its mucus layer with a half-life of approximately 15-20 minutes, physically sweeping deposited drug toward the nasopharynx.

Advantages

  • Non-invasive. No needles, no pain.
  • Fast onset. The rich nasal blood supply provides rapid absorption --- often within 10-15 minutes.
  • Bypasses first-pass metabolism. Direct absorption into systemic circulation.
  • Nose-to-brain delivery. Peptides deposited in the upper nasal cavity, near the olfactory region, may access the CNS via the olfactory nerve pathway, bypassing the blood-brain barrier. This is an active area of research for neurological applications.

Disadvantages

  • Low bioavailability. Mucociliary clearance and limited membrane permeability keep absorption low for most peptides.
  • Dose volume limitations. Each nostril can accommodate roughly 100-150 microliters per spray. Larger doses require multiple sprays, which can reduce absorption efficiency.
  • Nasal irritation. Chronic use may cause mucosal drying, irritation, or epistaxis (nosebleeds).
  • Variability. Nasal congestion, allergies, and differences in spray technique affect absorption.

Key Peptides Using Nasal Route

  • Desmopressin (Stimate, DDAVP nasal spray) --- diabetes insipidus, nocturnal enuresis. Nasal bioavailability ~3-5%.
  • Calcitonin (Miacalcin nasal spray) --- osteoporosis. Nasal bioavailability ~3%.
  • Oxytocin nasal spray --- research use for social behavior studies, breastfeeding support.
  • Nafarelin (Synarel) --- GnRH agonist for endometriosis and central precocious puberty.

Topical and Transdermal Administration

Topical application delivers the peptide to the skin surface for local effects. Transdermal delivery aims to push the peptide through the skin and into systemic circulation.

The Skin Barrier

The skin's outermost layer, the stratum corneum, is a formidable barrier --- 10-20 micrometers of tightly packed, lipid-rich dead keratinocytes. This layer evolved to keep the environment out and body fluids in. For most peptides (hydrophilic, MW > 500 Da), passive diffusion through the stratum corneum is negligible.

Topical (Local) Delivery

For local effects (skin conditions, wound healing), topical peptide delivery can be effective because the target is the skin itself, not the systemic circulation. Copper peptides (GHK-Cu) for skin repair, palmitoyl peptides for anti-aging, and various growth factor peptides in wound healing products are applied topically and act locally without needing to reach the blood.

Transdermal (Systemic) Delivery

Achieving systemic peptide delivery through the skin requires technologies that breach or bypass the stratum corneum:

Microneedles. Arrays of microscale needles (100-1000 micrometers tall) that painlessly penetrate the stratum corneum and deliver the peptide into the viable epidermis or dermis. Dissolving microneedle patches that release insulin, GLP-1 agonists, or PTH analogs are in clinical development.

Iontophoresis. A low-level electrical current drives charged peptide molecules through the skin barrier. Works best for small, charged peptides.

Sonophoresis. Ultrasound creates transient cavitation in the stratum corneum, temporarily increasing permeability.

Chemical penetration enhancers. Compounds like oleic acid, DMSO, or fatty acid esters disrupt stratum corneum lipid organization, creating channels for peptide transport.

Advantages

  • Non-invasive and painless (for topical and microneedle patches).
  • Avoids GI degradation and first-pass metabolism.
  • Sustained release potential. Transdermal patches can deliver peptide continuously over hours to days.
  • Large surface area. The skin covers 1-2 square meters, providing ample absorption area.

Disadvantages

  • Very low bioavailability for passive transdermal delivery without enhancement technologies.
  • Limited to small peptides for most current technologies. Peptides above ~10 kDa are difficult to deliver even with enhancement.
  • Skin irritation from penetration enhancers or iontophoresis.
  • Regulatory complexity. Microneedle and device-based delivery systems face more complex regulatory pathways than simple injections.

Key Applications

  • Topical copper peptides and growth factors --- wound healing, skin repair
  • Teriparatide microneedle patches --- in clinical development for osteoporosis
  • Insulin microneedle patches --- in preclinical/early clinical development

Emerging Routes: Pulmonary, Buccal, and Rectal

Pulmonary (Inhaled) Delivery

The lungs present an enormous absorption surface (70-140 square meters), thin alveolar epithelium (0.1-0.2 micrometers), and rich blood supply. Inhaled insulin (Exubera, then Afrezza) demonstrated that pulmonary peptide delivery is feasible:

  • Exubera (Pfizer) was the first inhaled insulin, approved in 2006 but withdrawn in 2007 due to poor commercial uptake and lung safety concerns.
  • Afrezza (MannKind) uses Technosphere microparticles for ultra-rapid absorption, reaching peak insulin levels within 12-15 minutes --- faster than any injectable insulin.

Pulmonary bioavailability for insulin is approximately 10-20%, significantly higher than oral delivery. The main concerns are long-term pulmonary safety (particularly in smokers), dose variability with breathing patterns, and device design.

Buccal and Sublingual Delivery

The oral mucosa (inner cheek and under the tongue) provides direct absorption into systemic circulation, bypassing GI degradation and first-pass metabolism. The sublingual mucosa is thinner and more permeable than the buccal mucosa.

Bioavailability through the oral mucosa is generally low for large peptides (1-5%) but can be enhanced with mucoadhesive formulations and absorption enhancers. Buccal delivery is being explored for oxytocin, insulin, and GLP-1 agonists.

Rectal Delivery

The lower rectum drains directly into the systemic circulation via the inferior rectal veins, bypassing the hepatic portal system. Rectal peptide delivery avoids stomach acid and most proteases. Bioavailability can be moderate (5-20% for some peptides), but patient acceptance is low in most markets, limiting clinical development.

Bioavailability Comparison

RouteTypical BioavailabilityOnset TimeFirst-Pass EffectSelf-Administration
Intravenous100% (by definition)SecondsNoneNo (clinical setting)
Subcutaneous50-100%15-60 minNoneYes (pens, auto-injectors)
Intramuscular50-100%10-30 minNoneDifficult (some sites)
Pulmonary10-20%5-15 minNoneYes (inhaler device)
Nasal1-10%10-15 minNoneYes (nasal spray)
Buccal/Sublingual1-5%15-30 minMinimalYes (tablet/film)
Rectal5-20%15-30 minPartialYes (suppository)
Transdermal<1% (passive); 5-20% (enhanced)30 min - hoursNoneYes (patch)
Oral<1-2% (most peptides)30-90 minYesYes (tablet/capsule)
TopicalLocal effect; negligible systemicVariableNoneYes (cream/gel)

These values are generalizations. Actual bioavailability depends heavily on the specific peptide, formulation, and any absorption-enhancing technology used.

Which Peptides Use Which Routes

PeptidePrimary RouteWhy This Route
Semaglutide (Ozempic)SC injection (weekly)Lipidation enables weekly dosing; high bioavailability
Semaglutide (Rybelsus)OralSNAC enhancer; ~1% bioavailability sufficient due to high potency
Tirzepatide (Mounjaro)SC injection (weekly)Lipidation with C20 fatty diacid; similar pharmacokinetic rationale to semaglutide
Insulin (various)SC injection; inhaled (Afrezza)SC is standard; pulmonary provides ultra-rapid onset for mealtime use
Liraglutide (Victoza)SC injection (daily)C16 fatty acid lipidation; shorter half-life than semaglutide
Tesamorelin (Egrifta)SC injection (daily)GHRH analog; SC provides adequate bioavailability
DesmopressinOral, nasal spray, SC/IVAvailable in multiple formulations; nasal is most common for outpatient use
CalcitoninNasal spray, SC injectionNasal spray preferred for osteoporosis (convenience); SC for acute hypercalcemia
Octreotide (Sandostatin)SC injection, IM depot (LAR)SC for acute dosing; LAR microsphere depot for monthly IM injection
Cyclosporine A (Neoral)OralCyclic, N-methylated structure enables ~30% oral bioavailability
GnRH analogs (leuprolide, goserelin)SC/IM depotDepot formulations provide 1-6 month sustained release
OxytocinIV (labor induction), nasal (research)IV for precise clinical dosing; nasal for non-invasive research use

For guidance on peptide reconstitution and injection technique, see our step-by-step guides.

FAQ

Why are most peptide drugs injected rather than taken orally?

The GI tract is a proteolytic gauntlet: stomach acid, pepsin, trypsin, chymotrypsin, and brush border peptidases destroy most peptides before they can be absorbed. The intestinal epithelium also blocks passive diffusion of large, hydrophilic molecules. Together, these barriers typically reduce oral peptide bioavailability to below 1-2%, which is insufficient for most peptides.

How does oral semaglutide work with such low bioavailability?

Oral semaglutide (Rybelsus) is co-formulated with SNAC, an absorption enhancer that raises local stomach pH and promotes transcellular absorption. Even at ~1% bioavailability, the drug works because semaglutide is extremely potent --- nanogram quantities are sufficient to activate GLP-1 receptors. The 14 mg oral dose delivers enough absorbed drug to produce effects comparable to the 1 mg SC dose.

What is the difference between subcutaneous and intramuscular injection?

SC injection goes into the fatty tissue under the skin; IM injection goes into muscle. IM absorption is faster (higher blood flow in muscle), but SC absorption is more sustained and predictable. SC injection is easier to self-administer (shallower needle depth, more accessible sites) and is the standard for most at-home peptide therapies.

Can peptides be delivered through the skin?

Passive transdermal delivery of peptides is very limited because the stratum corneum blocks hydrophilic macromolecules. Active technologies --- microneedle patches, iontophoresis, sonophoresis --- can breach this barrier and achieve moderate bioavailability. Microneedle patches for insulin and teriparatide are in clinical development. For topical (local) effects on the skin itself, peptides can be effective without needing to reach systemic circulation.

What is nose-to-brain delivery?

When peptides are deposited in the upper nasal cavity near the olfactory epithelium, they may travel along the olfactory nerve directly to the brain, bypassing the blood-brain barrier. This route is being explored for peptide drugs targeting neurological conditions, including GLP-1 agonists for neurodegeneration and insulin for Alzheimer's disease.

Which route has the fastest onset of action?

Intravenous injection provides the fastest onset (seconds). Among non-invasive routes, inhaled (pulmonary) delivery is fastest (5-15 minutes), followed by nasal (10-15 minutes), and sublingual (15-30 minutes). Oral administration is slowest (30-90 minutes to reach therapeutic levels).

The Bottom Line

The route of administration is not a minor detail --- it is a fundamental design parameter that shapes every aspect of peptide therapy. Subcutaneous injection remains the workhorse, offering high bioavailability with the convenience of self-administration. Oral delivery is possible but requires either exceptional peptide potency (semaglutide), inherent membrane permeability (cyclosporine), or novel absorption technologies. Nasal, pulmonary, and transdermal routes occupy niches where their specific advantages (fast onset, non-invasiveness, CNS access) outweigh their lower bioavailability.

The trend in the field is clear: reduce injection burden. Approximately 70 peptide drug candidates are currently in clinical development using oral, nasal, and inhalation routes. Microneedle patches, ingestible injection devices, and next-generation absorption enhancers are in the pipeline. The peptides themselves are being engineered --- through cyclization, lipidation, and other modifications --- to survive routes that would destroy unmodified molecules.

For anyone using or studying peptide therapeutics, the question is never just "which peptide?" It is always "which peptide, delivered how?" The route determines the bioavailability, and the bioavailability determines the dose, the cost, and ultimately whether the treatment works.

References

  1. Basics and recent advances in peptide and protein drug delivery. (2014). Journal of Drug Targeting, 21(2), 87-96. PMC3956587

  2. Bachem. Bioavailability of Peptides. bachem.com

  3. Brayden, D.J., et al. (2020). Oral semaglutide as an anti-diabetic drug: The story so far. Pharmacological Reviews, 72(1), 47-92.

  4. Buckley, S.T., et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 10(467), eaar7047.

  5. Han, Y., et al. (2020). Transdermal delivery of peptide and protein drugs: Strategies, advantages and disadvantages. Journal of Drug Delivery Science and Technology, 60, 102108. doi:10.1016/j.jddst.2020.102108

  6. Khan, N., et al. (2024). Strategies for transportation of peptides across the skin for treatment of multiple diseases. Therapeutic Delivery, 16(1), 47-73. PMC11703487

  7. Rajput, A., et al. (2025). Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances. Pharmaceutics, 17(4), 397. PMC12030352

  8. Chatterjee, S., et al. (2023). A comprehensive review of advanced nasal delivery: Specially insulin and calcitonin. Journal of Pharmaceutical and Biomedical Analysis, 232, 115427. doi:10.1016/j.jpba.2023.115427

  9. Dhankhar, S., et al. (2025). Transmucosal drug delivery: prospects, challenges, advances, and future directions. Expert Opinion on Drug Delivery. doi:10.1080/17425247.2025.2470224

  10. Lau, J., et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry, 58(18), 7370-7380.

  11. Therapeutics peptides: current applications and future directions. (2022). Signal Transduction and Targeted Therapy, 7, 48. doi:10.1038/s41392-022-00904-4

  12. Marre, M., et al. (2024). The limitation of lipidation: Conversion of semaglutide from once-weekly to once-monthly dosing. PNAS, 121(48), e2415815121. doi:10.1073/pnas.2415815121